Myocardial and Pericardial Disease
- Blood Type May Predict VTE Risk Among Patients With Cancer
- Apixaban Is Not Inferior to Warfarin for Post-MI LVT
- Risk Prediction Tool May Identify Patients With MM at a High Risk for VTE
- Strong Recommendations Lacking in Perioperative Antiplatelet Management
- Machine-Learning Model May Reduce Misdiagnosis in Heparin-Induced Thrombocytopenia
- Apixaban Compared With Dalteparin in Cancer-Related VTE
- Efgartigimod Associated With Improved Platelet Counts in ITP
- Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE
- ACR: Opioids Raise Risk for VTE in Patients With Rheumatoid Arthritis
- Vaccination Status Not Associated With Acute Thromboembolism Risk in COVID-19
- Gab2 and MALT1 Influence Regulation of Thromboinflammation, DVT
- Venous Thromboembolism Rates Increasing in Patients Hospitalized With IBD
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
